Stock Quote Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Markets Stocks ETFs Tools Overview News Currencies International Treasuries Small Pharma Inc (OP: DMTTF ) 0.0941 UNCHANGED Streaming Delayed Price Updated: 2:05 PM EST, Feb 1, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.0941 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0941 Today's Range 0.0941 - 0.0941 52wk Range 0.0550 - 0.3328 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year Top News More News Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents February 01, 2023 After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc. Via Benzinga Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue February 01, 2023 From Small Pharma Inc. Via Globe NewsWire Performance YTD +28.90% +28.90% 1 Month +28.90% +28.90% 3 Month -24.72% -24.72% 6 Month +10.71% +10.71% 1 Year -43.52% -43.52% More News Read More Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings January 25, 2023 Via Benzinga Small Pharma Reports Fiscal Third Quarter 2023 Highlights January 25, 2023 Via PressReach Small Pharma Reports Fiscal Third Quarter 2023 Highlights January 25, 2023 From Small Pharma Inc. Via Globe NewsWire Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder January 25, 2023 From Small Pharma Inc. Via Globe NewsWire Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25 January 24, 2023 From Small Pharma Inc. Via Globe NewsWire Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous? January 11, 2023 Via Benzinga First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026 January 09, 2023 From Small Pharma Inc. Via Globe NewsWire Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More December 28, 2022 Via Benzinga This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage December 22, 2022 Via Benzinga Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property December 22, 2022 From Small Pharma Inc. Via Globe NewsWire Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing December 19, 2022 Via Benzinga How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study December 16, 2022 Via Benzinga First Patient Dosed in Small Pharma’s Drug Interaction Study December 15, 2022 From Small Pharma Inc. Via Globe NewsWire Small Pharma To Support University College London Research Project on Neuroplasticity December 14, 2022 From Small Pharma Inc. Via Globe NewsWire Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium December 08, 2022 From Small Pharma Inc. Via Globe NewsWire Psychedelic Stock Gainers And Losers From November 24, 2022 November 24, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 23, 2022 November 23, 2022 Via Benzinga Small Pharma to Participate in November Investor and Healthcare Conferences November 11, 2022 From Small Pharma Inc. Via Globe NewsWire Psychedelic Stock Gainers And Losers From November 8, 2022 November 08, 2022 Via Benzinga Compass Pathways, Allied Among Top Psychedelic Movers Of Today November 07, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 3, 2022 November 03, 2022 Via Benzinga Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today November 02, 2022 Via Benzinga This Novel Short-Acting Psychedelic Compound Is Ready For First Phase 1 Clinical Try-Out October 31, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
